Symposium Home Page

Inaugural Brain Cancer Symposium

September 30 – October 1, 2022
Ann Arbor, MI

The BioInnovations in Brain Cancer’s inaugural symposium is bringing together scientists to bridge the gap between brain cancer biology research and novel technological developments in order to advance the diagnosis and treatment of glioma to improve the lives of patients.

The symposium will take place at the University of Michigan – Ann Arbor Campus over two days on September 30th and October 1st.

Important Dates and Information:

Early bird reduced registration pricing ends July 1, 2022

The abstract submission deadline has been extended to July 17, 2022

Registration deadline is August 15, 2022

The University of Michigan has specific Covid-19 mitigation guidelines that must be followed for individuals visiting the campus. Please visit our Community and Visitors Webpage to learn more.

Register Today

Symposium Information

Click on the tiles to find out more information on symposium registration, hotel details, speakers and more.

Event Organization

Learn more about our BIBC program, the Symposium Organizers, Sponsorship, and the city of Ann Arbor

Invited Speakers

Keynote Speakers

Henry Ford neurosurgeon, Steven Kalkanis, M.D.

Steven Kalkanis, MD, CEO of the Henry Ford Medical Group (HFMG) and Senior Vice President and Chief Academic Officer of Henry Ford Health System

Headshot of Justin Scot Hanes

Justin Hanes, PhD, Director, Center for Nanomedicine, Lewis J. Ort Professor of Ophthalmology at Johns Hopkins Medicine

Confirmed Symposium Speakers

Peter Fecci, MD, PhD, Duke University

Dolores Hambardzumyan, PhD, MBA, Icahn School of Medicine at Mount Sinai

Shawn Hervey-Jumper, MD, University of California San Francisco

Irina Balyasnikova, PhD, Northwestern University

Ali Shilatifard, PhD, Northwestern University

Ranjit Bindra, MD, PhD, Yale

Yon Son Betty Kim, MD, PhD, MD Anderson Cancer Center

Robert Prins, PhD, University of California Los Angeles

Shawn Hingtgen, PhD, University of North Carolina

Roland Friedel, PhD, Icahn School of Medicine at Mount Sinai

Balveen Kaur, PhD,  The University of Texas Health Science Center at Houston

David Reardon, MD, Dana-Farber Cancer Institute and Harvard Medical School

Hong Chen, PhD, Washington University in St. Louis

Ananth V. Annapragada, PhD, Texas Children’s Hospital

Jose Javier Bravo-Cordero, PhD, Icahn School of Medicine at Mount Sinai

Robert G. Thorne, PhD, Denali Therapeutics and the University of Minnesota – Minneapolis

Questions

Please reach out to us with any questions or concerns.

Email us